Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +55

What Investors Don’t Understand About Abbott Laboratories

AI-generated analysis

📈 Abbott Laboratories posted four consecutive EPS beats with adjusted Q1 2026 EPS reaching $1.15 against guidance of $5.38 to $5.58 for the full year.

💉 The FreeStyle Libre CGM franchise cleared $2.08 billion in Q1 2026, growing 13.8% as the global market is projected to expand from 12 million to 80 million users.

🏥 Abbott closed its $21 billion acquisition of Exact Sciences on March 23, 2026, launching a Cancer Diagnostics unit expected to generate $3 billion in incremental 2026 sales.

📉 The Nutrition segment declined 6.0% to $2.02 billion in Q1 2026, reflecting deliberate price adjustments and volume recovery strategies under CEO Robert Ford.

📊 Shares closed at $89.27, down 32.1% over one year, yet analysts maintain a buy consensus with a target price of $116.54.

⚖️ The company maintains a low beta of 0.607 and has increased dividends for 54 consecutive years, reinforcing its identity as a defensive dividend aristocrat.

Bullish Signals
  • Abbott delivered four consecutive earnings beats with Q1 2026 adjusted EPS of $1.15, demonstrating consistent execution despite market headwinds.
  • The FreeStyle Libre CGM franchise generated $2.08 billion in revenue for Q1 2026, growing 13.8% and capturing a rapidly expanding global market.
  • Established Pharmaceuticals grew 13.2% while international sales rose 11.3%, indicating strong diversification beyond the Nutrition segment.
  • The $21 billion Exact Sciences acquisition is expected to contribute approximately $3 billion in incremental sales for 2026, validating the strategic pivot toward oncology diagnostics.
Risk Factors
  • The Nutrition segment, a core legacy business, fell 6.0% year-over-year to $2.02 billion due to deliberate price reductions and volume challenges.
  • Shares are trading at a significant discount to analyst consensus, down 32.1% over the past year, suggesting the market may still undervalue the company's transformation.
  • The company faces genuine competitive pressure from DexCom in the CGM space, which could impact FreeStyle Libre's long-term growth trajectory.
Full Analysis
Abbott Laboratories (NYSE:ABT) is trading at a forward P/E of 17x with shares down significantly from analyst targets, despite posting four consecutive earnings beats and maintaining its status as an S&P 500 Dividend Aristocrat. The company has successfully pivoted toward high-growth medical devices, with the FreeStyle Libre continuous glucose monitor franchise generating $2.08 billion in Q1 2026 alone, representing a 13.8% quarter-over-quarter increase. The firm recently closed its approximately $21 billion acquisition of Exact Sciences on March 23, 2026, creating a new Cancer Diagnostics unit anchored by Cologuard. Management projects this strategic move will drive roughly $3 billion in incremental sales for 2026, while established pharmaceuticals and international segments also posted double-digit growth rates. While the market still views Abbott as a defensive bond proxy due to its low beta of 0.607 and long dividend history, CEO Robert Ford argues this narrative underprices the company's transformation. Challenges remain in the Nutrition segment, which fell 6% year-over-year, alongside competitive pressures from DexCom and macroeconomic factors like foreign exchange fluctuations and China procurement policies.